Pioglitazone did not reduce macrovascular complications and increased HF in type 2 diabetes with macrovascular disease
W. L Isley
Evid Based Med 2006
11: 47.
Files in this Data Supplement:
view PDF -
Pioglitazone vs. placebo for type 2 diabetes and macrovascular events.